Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Jing Yan Tang"'
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0306863 (2024)
BackgroundAlthough clear cell sarcoma of kidney (CCSK) is rare, it is the second most common renal tumor in children after Wilms' tumor. NWTS and SIOP are two major groups which had made tremendous efforts on renal tumors, but the strategies are diff
Externí odkaz:
https://doaj.org/article/4cf30ef58af54688b3f4d21b8599bff3
Autor:
Jing Yan Tang, Shang Li, Zhen Hua Li, Zai Jun Zhang, Guang Hu, Lorita Chi Veng Cheang, Deepa Alex, Maggie Pui Man Hoi, Yiu Wa Kwan, Shun Wan Chan, George Pak Heng Leung, Simon Ming Yuen Lee
Publikováno v:
PLoS ONE, Vol 5, Iss 7, p e11822 (2010)
BACKGROUND: Angiogenesis plays an important role in a wide range of physiological processes, and many diseases are associated with the dysregulation of angiogenesis. Radix Astragali is a Chinese medicinal herb commonly used for treating cardiovascula
Externí odkaz:
https://doaj.org/article/31444afead2642cc9001352227ef51e6
Autor:
Meng-Meng, Yin, Rui-Chi, Wu, Jing, Gao, Shao-Yan, Hu, Xiao-Ming, Liu, Xiao-Fan, Zhu, Shu-Hong, Shen, Jing-Yan, Tang, Jing, Chen, Qun, Hu
Publikováno v:
Current Medical Science. 42:201-209
Cytogenetic abnormalities have been proven to be the most valuable parameter for risk stratification of childhood acute lymphoblastic leukemia (ALL). However, studies on the prevalence of cytogenetic abnormalities and their correlation to clinical fe
Autor:
Yi-Jin Gao, Yong-Jun Fang, Ju Gao, Jie Yan, Liang-Chun Yang, Ai-Guo Liu, Xiu-Li Ju, Jun Lu, Ya-Li Han, Jun Wang, Min Xie, Xia Guo, Jing-Yan Tang
Publikováno v:
Annals of hematology. 101(9)
The evidence for the safety and efficacy of adding rituximab to intensive chemotherapy in pediatric patients with aggressive mature B cell non-Hodgkin lymphoma/leukemia (B-NHL/B-AL) is not yet robust. In this prospective multi-institutional trial, 41
Autor:
Yonghong Zhang, Yi-Jin Gao, Dong-Tsamn Lin, Seiji Kojima, Shiann-Tarng Jou, Jing-Yan Tang, Jin Kyung Suh, Ling Jin, Jong Jin Seo, Yoshiyuki Takahashi
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
PurposeThe presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.Materials and MethodsMedical records of 749 pe
Autor:
Jing-Yan Tang, Jie Zhao, Min-Zhi Yin, Bo Yv, Yingwen Zhang, Yi-Jin Gao, Yi Yang, Jing Wang, Haizhong Feng, Yanxin Li
Background: MYCN is an identified driver and important prognosticator of neuroblastoma and performs biological function at protein level. At present, most detection methodologies focus on MYCN DNA level and fail to detect MYCN protein expression for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cc9514a7c29ba17a759a5c65aef6e02
https://doi.org/10.21203/rs.3.rs-62365/v1
https://doi.org/10.21203/rs.3.rs-62365/v1
Publikováno v:
Journal of Pediatric Hematology/Oncology. 40:e9-e12
We reported the outcome of 150 children newly diagnosed with multisystem langerhans cell histiocytosis following a langerhans cell histiocytosis-II-based protocol (arm B). However, the continuation treatment was extended to 56 weeks and etoposide was
Autor:
Zhuo, Wang, Shu-Hong, Shen, Yan-Jing, Tang, Hui-Liang, Xue, Wen-Ting, Hu, Ci, Pan, Jing-Yan, Tang, Long-Jun, Gu, Jing, Chen
Publikováno v:
Zhongguo Dang Dai Er Ke Za Zhi
OBJECTIVE: To study the clinical effect of the SCMC APL-2010 regimen in the treatment of acute promyelocytic leukemia (APL) in children. METHODS: A retrospective analysis was performed for the clinical data of 44 children with APL who received treatm
Publikováno v:
BMC Microbiology. 11/16/2016, Vol. 16, p1-15. 15p.
Autor:
Jie, Zhao, Jian-Wei, Liang, Hui-Liang, Xue, Shu-Hong, Shen, Jing, Chen, Yan-Jing, Tang, Li-Sha, Yu, Huan-Huan, Liang, Long-Jun, Gu, Jing-Yan, Tang, Ben-Shang, Li
Publikováno v:
Leukemia. 33(6)
Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q22;q21), resulting in a PML-RARA fusion that is the master driver of APL. A few cases that cannot be identified with PML-RARA by using conventional methods (karyotype analysis, FISH, an